Windward Bio Group AG (NASDAQ:WWB – Get Free Report) Director Otello Stampacchia acquired 1,750,000 shares of the business’s stock in a transaction on Monday, November 16th. The shares were bought at an average price of $17.00 per share, with a total value of $29,750,000.00. Following the completion of the transaction, the director directly owned 875,000 shares of the company’s stock, valued at approximately $14,875,000. The trade was a -200.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Windward Bio Group Price Performance
Shares of NASDAQ:WWB opened at $22.64 on Thursday. Windward Bio Group AG has a 12-month low of $18.35 and a 12-month high of $33.99.
About Windward Bio Group
Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
Recommended Stories
- Five stocks we like better than Windward Bio Group
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Windward Bio Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windward Bio Group and related companies with MarketBeat.com's FREE daily email newsletter.
